180
Participants
Start Date
May 31, 2025
Primary Completion Date
May 31, 2027
Study Completion Date
May 31, 2027
Low-dose H057+standard-of-care
Subjects are administered low-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
High-dose H057+standard-of-care
Subjects are administered high-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
H057 placebo+standard-of-care
Subjects are administered inhaled H057 placebo, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
Fuyang Hospital Of Anhui Medical University, Fuyang
Hefei First People's Hospital, Hefei
Fujian Medical University Union Hospital, Fuzhou
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
Peking University Shenzhen Hospital, Shenzhen
Affiliated hospital of Youjiang Medical University For Nationalities, Baise City
Hebei General Hospital, Shijiazhuang
Nanyang Second General Hospital, Nanyang
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Yichang Central People's Hospital, Yichang
The second Xiangya Hospital of Central South University, Changsha
Changzhou First People's Hospital, Changzhou
Jiujiang No.1 People's Hospital, Jiujiang
Sichuan Provincial People's Hospital, Chengdu
Deyang People's Hospital, Deyang
Hangzhou First People's Hospital, Hangzhou
Jinhua Municipal Central Hospital, Jinhua
Ningbo No.2 Hospital, Ningbo
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Shanghai Huilun Pharmaceutical Co., Ltd.
INDUSTRY